Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-κB p65

Abstract

Inflammatory bowel disease is thought to be regulated by the balance between Th1 and Th2 cytokines secreted by T cells, and NF-κB p65 also plays a predominant role in the intestinal inflammation. We evaluated the potency of oxymatrine, one of active components of Sophora Root, in inhibiting the immune responses and inflammation in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The inflammation was markedly ameliorated in the oxymatrine-treated rats. The level of IL-2 was increased and that of IL-10 was decreased in colon tissue in the rat model, which was reversed by the treatment of oxymatrine. Moreover, the elevated expression of NF-κB p65 in colon tissue in the model was also improved by oxymatrine treatment. Our results suggest that oxymatrine might be beneficial for the abnormal immune responses and inflammation by regulating the unbalance of Th1 and Th2 cytokines secretion and inhibiting the expression of NF-κB p65 in colon tissue.

Keywords

colitis / oxymatrine / interleukin 2 (IL-2) / interleukin 10 (IL-10) / nuclear factor-κB p65

References

[1] PodolskyD. K.. Inflammatory bowel disease. N Engl J Med, 2002, 347(6): 417-429

[2] HechtG. A.. Inflammatory Bowel disease—Live transmission. N Engl J Med, 2008, 358(5): 528-530

[3] FrankD. N., St AnandA. L., FeldmanR. A., et al.. Molecu-lar-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc Natl Acad Sci USA, 2007, 104(34): 13780-13785

[4] BaumgartD. C., SandbornW. J.. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369(9573): 1641-57

[5] LoftusE. V.Jr.. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology, 2004, 126(6): 1504-1517

[6] FanH., QiuM. Y., MeiJ. J., et al.. Effects of Four Regulating intestines Prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J Gastroenterol, 2005, 11(31): 4800-4806

[7] BaumgartD. C., CardingS. R.. Inflammatory bowel disease: cause and immunobiology. Lancet, 2007, 369(9573): 1627-1640

[8] ItoH., HirotaniT., YamamotoM., et al.. Kishimoto T.Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T cell apoptosis1m a murmemodel of Crohn’s disease. J Gastroenterol, 2002, 37(Suppl4): 56-61

[9] SchmidtC., MarthT., WittigB. M., et al.. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology, 2002, 70(3): 177-183

[10] LochnerM., ForsterI.. Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology, 2002, 70(3): 164-169

[11] BaeuerleP. A., BaltimoreD.. NF-κB: ten years after. Cell, 1996, 87(1): 13-20

[12] SenP., WalletM. A., YiZ., et al.. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood, 2007, 109(2): 653-60

[13] NeurathM. F., FussI., SchürmannG., et al.. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel dis-ease. Ann NY Acad Sci, 1998, 859(17): 149-159

[14] NeurathM. F., PetterssonS., Meyer zum BüschenfeldeK. H., et al.. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med, 1996, 2(9): 998-1004

[15] ZhengP., NiuF. L., LiuW. Z., et al.. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J Gastroenterol, 2005, 11(31): 4912-4915

[16] MorrisG. P., BeckP. L., HerridgeM. S., et al.. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989, 96(3): 795-803

[17] DikopoulosN., SchmidR. M., BachemM., et al.. Bile synthesis in rat models of inflammatory bowel diseases. Eur J Clin Invest, 2007, 37(3): 222-230

[18] WallaceJ. L., MacNaughtonW. K., MorrisG. P., et al.. Inhibition of leukot-riene synthesis markedly accelerates healing in a rat model of in-flammatory bowel disease. Gastroenterology, 1989, 96(1): 29-36

[19] Ten HoveT., CorbazA., AmitaiH., et al.. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production. Gastroenterology, 2001, 121(6): 1372-1379

[20] Te VeldeA. A., VerstegeM. I., HommesD. W.. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis, 2006, 12(10): 995-999

[21] AbadC., MartinezC., JuarranzM. G., et al.. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology, 2003, 124(4): 961-971

[22] IijimaH., NeurathM. F., NagaishiT., et al.. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med, 2004, 199(4): 471-482

[23] HwangE. S., HongJ. H., GlimcherL. H.. IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J Exp Med, 2005, 202(9): 1289-1300

[24] MullinG. E., LazenbyA. J.. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology, 1992, 102(5): 1620-1627

[25] RennickD. M., FortM. M.. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflamma-tion. Am J Physiol Gastrointest Liver Physiol, 2000, 278(6): G829-G833

[26] FedorakR. N., GanglA., ElsonC. O., et al.. Recombinant human inter-leukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology, 2000, 119(6): 1473-1482

[27] BaeuerleP. A., HenkelT.. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol, 1994, 12: 141-179

[28] HuangW.C., ChenJ. J., ChenC. C.. c-Src-dependent tyrosine phosphory-lation of IKKbeta is involved in tumor necrosis fac-tor-alpha-induced intercellular adhesion molecule-1 expression. J Biol Chem, 2003, 278(11): 9944-9952

[29] WangP., WuP., SiegelM. I., et al.. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem, 1995, 270(16): 9558-9563

[30] AbreuM. T., VoraP., FaureE., et al.. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterialimmatory gene expression in response to bacterial lipopolysaccharide. J Immunol, 2001, 167(3): 1609-1616

[31] TakP. P., FiresteinG. S.. NF-KB: a key role in inflammatory diseases. J Clin Invest, 2001, 107(1): 7-11

[32] SchreiberS., NikolausS., HampeJ.. Activation of nuclear factor kap-paB inflammatory bowel disease. Gut, 1998, 42(4): 477-484

[33] MatsunagaT., HokariS., KoyamaI., et al.. NF-kappaB activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun, 2003, 303(1): 313-319

[34] ZaninoniA., ImperialiF. G., PasquiniC., et al.. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol, 2003, 31(3): 185-190

[35] ChenY. M., TuC. J., HungK. Y., et al.. Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappaB down-regulation. Br J Pharmacol, 2003, 138(3): 950-958

[36] KisA., YellonD. M., BaxterG. F.. Role of nuclear factor-kappaB activa-tion in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol, 2003, 138(3): 894-900